This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of +76.92% and +7.52%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
by Zacks Equity Research
NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
by Nalak Das
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeuroPace (NPCE) delivered earnings and revenue surprises of 19.23% and 2.87%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, NeuroPace (NPCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 14.29% and 0.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of 3.70% and 9.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 19.35% and 1.05%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -85.71% and 4.16%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of 8.33% and 0.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia Healthcare (ACHC) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of -11.11% and 0.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Integer (ITGR) Misses Q4 Earnings Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -2.05% and 0.75%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Matches Q3 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 0% and 0.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
NeuroPace (NPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.5% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes NeuroPace (NPCE) a New Buy Stock
by Zacks Equity Research
NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for NeuroPace (NPCE) points to a 54.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeuroPace (NPCE) delivered earnings and revenue surprises of 26.92% and 8.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 50.98% and 6.16%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength?
by Zacks Equity Research
NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
by Zacks Equity Research
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.
Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of -22.22% and 12.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of -555.81% and 27.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?